InspireMD, Inc. (NYSE MKT:NSPR, NSPR.WS), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that in conjunction with the 1-for-25 reverse stock split announced last week following the Company’s special meeting of stockholders, the number of shares of common stock of InspireMD receivable upon exercise of one warrant currently trading on the NYSE MKT and the exercise price will adjust from 1 share at the exercise price of $0.20 per share of common stock to 1/25 of one share at the exercise price of $0.20 per 1/25 of one share of common stock, effective at 5:00 p.m. ET on October 7, 2016. Warrants may only be exercisable for a whole number of shares of common stock. Warrants exercised on or prior to October 7 will be on a pre-adjusted basis.

InspireMD’s warrants will continue to trade on the NYSE MKT under the symbol “NSPR.WS.” The CUSIP number for the Company’s warrants will remain 45779A 119.

Additional information regarding these warrant adjustments can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 18, 2016, a copy of which is also available at www.sec.gov or at www.inspiremd.com under the SEC Filings tab located on the Investors page.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNetTM technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuardTM), neurovascular, and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants are quoted on the NYSE MKT under the ticker symbol NSPR.WS.